A Guideline-Grounded Multi-Agent Framework for Personalized Exercise Prescription from Clinical and Wearable Data
Authors: Xintong Li, Yufen Lin, Yuhua Wu, Fengran Wang, Minxiao Wang, Rebecca A. Gary, Jacob Kariuki, James Smith, Sandra A. Billinger, Canhua Xiao, Xiao Hu, Runze Yan
Organizations: Center for Data Science, Nell Hodgson Woodruff School of Nursing, Emory University · Department of Computer Science, Emory University · Nell Hodgson Woodruff School of Nursing, Emory University · Cancer Prevention and Control Research Program, Winship Cancer Institute, Emory University · Lillian Carter Center for Global Health and Social Responsibility, Nell Hodgson Woodruff School of Nursing, Emory University · Lancaster Medical School, Lancaster University · Department of Neurology, University of Kansas Medical Center · Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University
Translating population-level exercise guidance into individualized prescriptions requires integrating clinical and wearable data, including diagnoses, medications, functional limitations, and baseline activity, with condition-specific recommendations, a process difficult to scale beyond specialist rehabilitation settings. We developed FITTER, a multi-agent framework that integrates these data with condition-specific guidance to generate personalized FITT-VP prescriptions and applies deterministic safety audit and repair to correct rule-checkable violations. We evaluated FITTER using data from 400 All of Us participants (300 cancer, 100 stroke) against five LLM comparators through computational evaluation, ablation, and structured clinician review. FITTER achieved 98.5% safety-constraint compliance versus 75.8-85.8% for comparators and showed greater quantitative dosing precision and guideline alignment. Cancer-cohort ablation identified safety audit and repair as the largest contributor to safety-constraint compliance. Clinicians reviewed 80 prescriptions across safety, personalization, instruction concreteness, anticipated effectiveness, and clinical acceptability. FITTER provides a clinician-facing approach integrating clinical and wearable data, guidance, and explicit safety constraints.
Figures & tables
Cancer cohort
Stroke cohort
Characteristic
Full
Evaluation
SMD
Full
Evaluation
SMD
( n=3,764 )
( n=300 )
( n=790 )
( n=100 )
Age, years
67.0 [58.0, 73.0]
66.0 [57.0, 72.2]
-0.052
67.0 [57.0, 73.0]
66.5 [56.0, 72.0]
-0.062
Body mass index, kg/m 2
28.1 [24.7, 32.5]
28.3 [25.0, 32.2]
0.027
28.6 [25.0, 33.8]
30.5 [25.4, 34.1]
0.133
Systolic blood pressure, mmHg
127.0 [119.0, 136.3]
127.6 [118.5, 138.0]
0.024
126.3 [118.1, 134.0]
124.5 [120.5, 134.5]
0.071
Diastolic blood pressure, mmHg
74.0 [69.0, 79.0]
73.8 [68.0, 78.9]
-0.044
73.1 [68.0, 78.0]
73.2 [69.4, 77.5]
0.061
Table 1: Characteristics of the eligible cancer and stroke cohorts and the two randomly selected evaluation samples comprising 400 participants. Continuous variables are reported as median [Q1, Q3] and categorical variables as n (%). Pain, fatigue, general health and sleep variables are self-reported. Standardized mean differences (SMDs) compare each diagnosis-specific evaluation sample with its eligible source cohort; absolute values below 0.10 indicate very small differences and values below 0.20 indicate small differences.
Figure 1: Computational evaluation across the 400 samples. a , Proportion of prescriptions with no detected safety-constraint violation by an independent model assessor. b , Instruction-concreteness composite (0–1). c , Guideline alignment, the embedding (cosine) similarity between each FITT-VP component and the guideline passages, averaged across components to give one value per prescription. FITTER is compared with five LLM comparators. Error bars show 95% confidence intervals. Asterisks indicate Holm-adjusted significance versus FITTER ( ∗P<0.05;∗∗∗P<0.001)
Table 2: Cross-system comparison across 400 matched participant profiles. Each metric was first tested with a Friedman or Cochran omnibus test across the six systems, then FITTER was compared with each comparator, and the five resulting P values were Holm-adjusted. Differences are FITTER minus comparator, so positive values favor FITTER. The pairwise measure is the matched-pairs rank-biserial correlation for the continuous metrics and the discordant-pair counts (FITTER safe/comparator safe) for the binary safety outcome. Confidence intervals are from 10,000 bootstrap resamples of the paired differences.
Figure 2: Clinician evaluation of 80 FITTER prescriptions. Each prescription was rated by one clinician reviewer on five aspects using a yes/partial/no scale. Values are mean normalized scores on a 0–100 scale, with yes, partial, and no assigned values of 100, 50, and 0, respectively.
“Only includes cardiorespiratory activity. Other types of exercise (e.g., strength) should be included as per guidelines.”
Equipment access or stated goal not fully reflected in the plan
19
“The patient does not have access to a recumbent cycle.”
Starting dose could be better aligned with measured baseline activity
14
“The patient is already fairly active, the starting intensity and dose is too low.”
Less detail provided for non-aerobic than aerobic components
13
“No specific exercises, sets, or reps for strength exercise. RPE may not be appropriate for strength exercises.”
Additional functional detail requested to assess the plan
13
“I would need more information on the patient’s level of disability and functional ability.”
Clinical considerations outside the structured input
12
“Would be concerned about fentanyl use around exercise time, could be a fall risk.”
Table 3: Themes raised in at least ten of the 55 reviews with free-text comments. A review could contribute to more than one theme. Representative comments are reproduced verbatim apart from minor spelling corrections.
Condition
Judged safe
Difference
Holm p
Full FITTER
99.0%
reference
—
No guideline retrieval
82.0%
-17.0 pp
8.6×10−14
No model-assisted safety review
76.3%
-22.7 pp
2.2×10−18
No deterministic audit and repair
62.0%
-37.0 pp
9.6×10−31
Table 4: Ablation analysis using 300 cancer participant profiles. Full FITTER and three ablation variants were assessed by the percentage of prescriptions meeting all specified safety constraints. Each variant removed one component, and all four conditions used the same participant profiles and model assessor. Differences are ablation variant minus full FITTER, in percentage points (pp). Cochran Q=137.9 on 3 degrees of freedom, p=1.1×10−29 ; exact McNemar tests against full FITTER are Holm-adjusted.
Figure 3: FITTER workflow. Clinical, functional, medication, and wearable data form a structured participant profile. Pre-generation screening produces safety constraints; five sequential agents then generate Type, Frequency, Intensity and Time, Volume, and Progression using retrieved guideline passages. After generation, the complete FITT-VP prescription is checked against those constraints; detected violations are corrected, producing the final structured prescription.
Agent
Decision and downstream output
Type
Selects aerobic, resistance, flexibility, and neuromotor components and names the prescribed activities.
Frequency
Sets initial and target sessions per week for each included component.
Intensity and Time
Sets initial and target RPE ranges, talk-test descriptions, session durations, and stop criteria.
Volume
Calculates initial and target weekly minutes for each component and for the full prescription.
Progression
Converts the prescription into six two-week blocks with progression, safety, and regression rules.
Table 5: Sequential FITTER agents and their structured outputs.
Constraint class
Actionable content
FITT-VP fields checked
Intensity limit
Permitted RPE or heart-rate range, including a prohibition on vigorous exercise
Intensity; Progression
Activity restriction
Prohibited exercise component or named activity
Type; Progression
Frequency, time, or volume limit
Bounds on sessions per week, minutes per session, or weekly minutes
Frequency; Time; Volume; Progression
Progression restriction
Permitted increases, required holds, or regression conditions
Progression; Volume
Stop criterion
Symptom or vital-sign condition requiring exercise to stop
Intensity and Time; Progression
Table 6: Standardized safety-constraint records stored in S and the FITT-VP fields governed by each class.